Status:
UNKNOWN
A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas
Lead Sponsor:
Zhaoyun Zhang
Conditions:
Pituitary Tumor
Eligibility:
All Genders
20-60 years
Phase:
NA
Brief Summary
Growth hormone secreting pituitary adenomas(GHomas) produce excessive GH, stimulating excessive insulin like growth factor 1(IGF-1) synthesis in the liver, thus causing multiple systemic complications...
Eligibility Criteria
Inclusion
- Patients with GHomas confirmed by surgery
- Patients who did not get biochemical remission: GH nadir after oral glucose tolerance test（OGTT）\>1.0ug/L or IGF-1 exceeds age matched normal range
Exclusion
- Patients who were allergic to rosiglitazone
- Patients with liver or kidney dysfunction, respiratory failure
- Patients with heart failure
- Patients with edema
- Patients with severe hyperlipidemia
- Patients with osteoporosis or a history of non traumatic fractures
- Patients with pregnancy and lactation
- Patients who had received radiation therapy within 3 years
- Patients who had participated in other clinical trials within 3 months
- Patients with other neoplastic diseases
- Patients with mental and neurological disorders
- Patients with other conditions which were believed not appropriate to take part in the clinical trial
Key Trial Info
Start Date :
October 16 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2018
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03309319
Start Date
October 16 2016
End Date
December 31 2018
Last Update
October 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital
Shanghai, Shanghai Municipality, China, 200040